DcR1 抗体
(Tumor Necrosis Factor Receptor Superfamily, Member 10c (TNFRSF10C))
The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain and a transmembrane domain, but no cytoplasmic death domain. This receptor is not capable of inducing apoptosis, and is thought to function as an antagonistic receptor that protects cells from TRAIL-induced apoptosis. This gene was found to be a p53-regulated DNA damage-inducible gene. The expression of this gene was detected in many normal tissues but not in most cancer cell lines, which may explain the specific sensitivity of cancer cells to the apoptosis-inducing activity of TRAIL. [provided by RefSeq, Jul 2008].
| Catalog no. | 产品 | 适用 | 宿主 / 克隆类型 | 应用 | 价格和交货时间 |
|---|---|---|---|---|---|
| DcR1 抗体 (C-Term) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DcR1 抗体 (N-Term) | 人 | 兔 Polyclonal |
|
|
|
| DcR1 抗体 (Extracellular Domain) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DcR1 抗体 (Extracellular Domain) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DcR1 抗体 | 小鼠 | 大鼠 Monoclonal |
|
|
|
| DcR1 抗体 (AA 26-236) (FITC) | 人 | 兔 Polyclonal |
|
|
|
| DcR1 抗体 (AA 26-236) (HRP) | 人 | 兔 Polyclonal |
|
|
|
| DcR1 抗体 (AA 26-236) (Biotin) | 人 | 兔 Polyclonal |
|
|
|
| DcR1 抗体 | 人 | 小鼠 Monoclonal |
|
|
|
| Recombinant DcR1 抗体 | 人 | 兔 Monoclonal |
|
|
|
| DcR1 抗体 (AA 26-236) | 人 | 小鼠 Monoclonal |
|
|
|
| DcR1 抗体 | 人 | 小鼠 Monoclonal |
|
|
|
| DcR1 抗体 | 人 | 兔 Polyclonal |
|
|
|
| DcR1 抗体 | 人 | 小鼠 Polyclonal |
|
|
|
| DcR1 抗体 (2nd Extracellular Domain) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DcR1 抗体 (AA 32-244) | 人 | 兔 Polyclonal |
|
|
|
| DcR1 抗体 | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| DcR1 抗体 | 人, 小鼠, 大鼠 | 兔 Monoclonal |
|
|
|
| DcR1 抗体 (AA 1-280) | 人 | 小鼠 Monoclonal |
|
|
|
| DcR1 抗体 (N-Term) | 人 | 兔 Polyclonal |
|
|
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- C-Term
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- IF (Immunofluorescence: 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 140-190, Extracellular Domain
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IF (Immunofluorescence: 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 90-140, Extracellular Domain
Primary Antibody
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- FITC
- 抗体亚型
- IgG
- 抗原表位
- AA 26-236
Primary Antibody
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- HRP
- 抗体亚型
- IgG
- 抗原表位
- AA 26-236
Primary Antibody
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- Biotin
- 抗体亚型
- IgG
- 抗原表位
- AA 26-236
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (Immunofluorescence: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Monoclonal
- 克隆
- A716
- 标记
- unconjugated
- 蛋白类型
- Recombinant Antibody
- 抗体亚型
- IgG, kappa
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- IF (Immunofluorescence: 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- AT1E12
- 标记
- unconjugated
- 抗体亚型
- IgG1 kappa
- 抗原表位
- AA 26-236
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IF (Immunofluorescence: 有验证图片)
- ELISA (ELISA: 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- 2nd Extracellular Domain
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (Immunohistochemistry: 有验证图片)
- ICC (Immunocytochemistry: 所列应用)
- IP (Immunoprecipitation: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 32-244
Primary Antibody
- FACS (Flow Cytometry: 有验证图片)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 标记
- unconjugated
- 抗体亚型
- IgG1
- 抗原表位
- AA 1-280
Primary Antibody
- WB (Western Blotting: 有验证图片)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- N-Term
Latest Publications for our DcR1 抗体
: "Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells." in: PLoS ONE, Vol. 14, Issue 4, pp. e0214847, (2019) (PubMed).
: "Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells." in: BMC cancer, Vol. 19, Issue 1, pp. 496, (2019) (PubMed).
: "TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells." in: Frontiers in immunology, Vol. 10, pp. 2044, (2019) (PubMed).
: "Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells." in: Cell death & disease, Vol. 8, Issue 8, pp. e3025, (2018) (PubMed).
: "TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis." in: Scientific reports, Vol. 7, Issue 1, pp. 5514, (2017) (PubMed).
: "Targeting Apoptotic Activity Against Prostate Cancer Stem Cells." in: International journal of molecular sciences, Vol. 18, Issue 8, (2017) (PubMed).
: "The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2." in: Molecular cell, Vol. 65, Issue 4, pp. 730-742.e5, (2017) (PubMed).
: "Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma." in: Stem cells translational medicine, Vol. 3, Issue 2, pp. 172-82, (2014) (PubMed).
: "Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes." in: The Journal of biological chemistry, Vol. 289, Issue 23, pp. 16576-87, (2014) (PubMed).
: "TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells." in: Anticancer research, Vol. 34, Issue 2, pp. 729-34, (2014) (PubMed).
: "Combination therapy with c-met inhibitor and TRAIL enhances apoptosis in dedifferentiated liposarcoma patient-derived cells." in: BMC cancer, Vol. 19, Issue 1, pp. 496, (2019) (PubMed).
: "TRAIL-Receptor 4 Modulates γδ T Cell-Cytotoxicity Toward Cancer Cells." in: Frontiers in immunology, Vol. 10, pp. 2044, (2019) (PubMed).
: "Dual role of DR5 in death and survival signaling leads to TRAIL resistance in cancer cells." in: Cell death & disease, Vol. 8, Issue 8, pp. e3025, (2018) (PubMed).
: "TRAIL regulatory receptors constrain human hepatic stellate cell apoptosis." in: Scientific reports, Vol. 7, Issue 1, pp. 5514, (2017) (PubMed).
: "Targeting Apoptotic Activity Against Prostate Cancer Stem Cells." in: International journal of molecular sciences, Vol. 18, Issue 8, (2017) (PubMed).
: "The TRAIL-Induced Cancer Secretome Promotes a Tumor-Supportive Immune Microenvironment via CCR2." in: Molecular cell, Vol. 65, Issue 4, pp. 730-742.e5, (2017) (PubMed).
: "Potential application of temozolomide in mesenchymal stem cell-based TRAIL gene therapy against malignant glioma." in: Stem cells translational medicine, Vol. 3, Issue 2, pp. 172-82, (2014) (PubMed).
: "Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexes." in: The Journal of biological chemistry, Vol. 289, Issue 23, pp. 16576-87, (2014) (PubMed).
: "TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cells." in: Anticancer research, Vol. 34, Issue 2, pp. 729-34, (2014) (PubMed).
Aliases for DcR1 抗体
TNF receptor superfamily member 10c (TNFRSF10C) 抗体CD263 抗体
DCR1 抗体
DCR1-TNFR 抗体
LIT 抗体
TNFRSF10C 抗体
TRAIL-R3 抗体
TRAILR3 抗体
TRID 抗体
您还需要查找其他产品吗？
You are here:
